International: +1-347-960-6455
Dementia Therapeutics - Pipeline Analysis 2018

Dementia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10097 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Neurology
Select License Type

Dementia is a group of neurological disorders which is characterized by impaired intellectual functioning. People having dementia generally lose the ability to maintain emotional control and solve the problems. Dementia can lead to the number of cognitive and psychological changes in the body such as memory loss, difficulty in communication, confusion and disorientation, depression, anxiety, personality changes, and hallucination. In this condition, the progressive loss of neurons leads to impaired mental functioning. People with dementia are in the need of prominent supervision to prevent them from harming others or themselves.

Charsire Biotechnology Corp. is in the process of developing CSTC 1 (BAC) for the treatment of dementia. Stemedica Cell Technologies Inc. is also in the process of developing human mesenchymal stem cells for the treatment of dementia. Asceneuron SA, and Avanir Pharmaceuticals Inc. are some other major companies involved in development of drugs for the management of dementia.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.